Patients with oligometastasis and favorable or intermediate-risk disease benefit the most.
-
RCC: SBRT with TKI is tolerable and prolongs OS -
The latest stories you need to know.
-
ASCO-GU 2021 — mCRPC: saracatinib-docetaxel combo disappoints Findings from a phase 1/2 trial.
-
ASCO-GU 2021 — As PSA screening declines, metastatic prostate cancer incidence climbs US states with larger screening declines have larger incidence increases.
-
MIBC: neoadjuvant cabazitaxel-cisplatin combo yields good response The combination is well tolerated and warrants further prospective evaluation.
-
The latest stories you need to know.
-
COVID-19 vaccination coverage in care homes may have a major role in the decision.
-
Prostate cancer: radiotherapy confers survival benefit in low metastatic burden Exploratory analysis of STAMPEDE trial.
-
Public expectations about the likelihood of easing restrictions need to be carefully managed, European Centre for Disease Prevention and Control cautions.
-
Maternal HPV status influences oral HPV persistence in offspring Should children be vaccinated earlier for HPV?
-
The latest stories you need to know.
-
COVID-19 Around the world weekly highlights: cases down, variants up, mixed success with vaccine rollout... COVID-19 Around the world weekly highlights: cases down, variants up, mixed success with vaccine rollout...
-
With misinformation casting a shadow over COVID-19 vaccine uptake, experts debate the issue.
-
Bladder cancer: enfortumab vedotin confers OS benefit in phase 3 FDA granted accelerated approval to enfortumab vedotin based on phase 2 results.